Cargando…
Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial
OBJECTIVES: The novel severe acute respiratory syndrome coronavirus 2 pandemic continues to spread globally without an effective treatment. In search of the cure, convalescent plasma (CP) containing protective antibodies from survivors of coronavirus disease 2019 (COVID-19) infection has shown poten...
Autores principales: | Khamis, Faryal, Al Arimi, Zainab, Al Naamani, Hamed, Al Bahrani, Maher, Pandak, Nenad, Al Bolushi, Zakaryia, Deenadayalan, Stephan S., Al Lawati, Adil, Al Salmi, Issa, Al-Zakwani, Ibrahim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OMJ
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491110/ https://www.ncbi.nlm.nih.gov/pubmed/34631155 http://dx.doi.org/10.5001/omj.2021.105 |
Ejemplares similares
-
Prevalence and predictors of in-hospital mortality of patients hospitalized with COVID-19 infection
por: Khamis, Faryal, et al.
Publicado: (2021) -
Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman
por: Khamis, Faryal, et al.
Publicado: (2020) -
The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman
por: Khamis, Faryal, et al.
Publicado: (2021) -
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
por: Khamis, Faryal, et al.
Publicado: (2021) -
Therapeutic plasma exchange in adults with severe COVID-19 infection
por: Khamis, Faryal, et al.
Publicado: (2020)